TMO Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Company profile
Ticker
TMO
Exchange
Website
CEO
Marc Casper
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
THERMO ELECTRON CORP
SEC CIK
Corporate docs
IRS number
42209186
TMO stock data
()
News
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Feb. 26, 2021: TWST, TMO, RHHBY, GOOGL, CDNA, TSM, SNPS, SNAP, ICE, NVS, PINS, REGN, ROKU, FLIR, AMZN, AAPL, FB, CRM, BABA, TCEHY
26 Feb 21
Cathie Wood's ARK Invest Posts Fund Sales For Tuesday, Feb. 23, 2021: SPLK, TMO, HIMS, GOOGL, Z, TCEHY, ROKU, TSM, SE, AMZN, AAPL, CRM
23 Feb 21
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Feb. 18, 2021: VCYT, TWST, TMO, CDNA, PACB, TCEHY, TWLO, SPLK, SSYS, BYDDY, AVAV, PSTG
18 Feb 21
Thermo Fisher Scientific Reports Purchase Of Propel Labs, No Terms Disclosed
17 Feb 21
Shortage Of Giant Sterile Liners Threatens Global Vaccines Rollout: FT
17 Feb 21
Press releases
Thermo Fisher Scientific Completes Acquisition of Mesa Biotech
26 Feb 21
Thermo Fisher Scientific to Present at 41st Annual Cowen Healthcare Conference on March 3, 2021
24 Feb 21
WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector
23 Feb 21
Thermo Fisher Scientific Increases Quarterly Dividend
23 Feb 21
Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs
17 Feb 21
Investment data
Securities sold
Number of investors
Calendar
24 Feb 21
2 Mar 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 21 | Boxer Michael A | Common Stock | Payment of exercise | Dispose F | No | No | 450.08 | 257 | 115.67K | 11,719 |
26 Feb 21 | Peter E Hornstra | Common Stock | Payment of exercise | Dispose F | No | No | 450.08 | 69 | 31.06K | 1,962 |
26 Feb 21 | Syed A. Jafry | Common Stock | Payment of exercise | Dispose F | No | No | 450.08 | 1,139 | 512.64K | 22,349 |
26 Feb 21 | Michel Lagarde | Common Stock | Payment of exercise | Dispose F | No | No | 450.08 | 570 | 256.55K | 24,574.205 |
26 Feb 21 | Mark Stevenson | Common Stock | Payment of exercise | Dispose F | No | No | 450.08 | 2,251 | 1.01M | 62,302 |
25 Feb 21 | Boxer Michael A | Common Stock | Payment of exercise | Dispose F | No | No | 451.47 | 288 | 130.02K | 11,976 |
25 Feb 21 | Peter E Hornstra | Common Stock | Payment of exercise | Dispose F | No | No | 451.47 | 59 | 26.64K | 2,031 |
25 Feb 21 | Peter E Hornstra | Common Stock | Payment of exercise | Dispose F | No | No | 451.47 | 28 | 12.64K | 2,090 |
25 Feb 21 | Syed A. Jafry | Common Stock | Payment of exercise | Dispose F | No | No | 451.47 | 790 | 356.66K | 23,488 |
25 Feb 21 | Michel Lagarde | Common Stock | Payment of exercise | Dispose F | No | No | 451.47 | 1,025 | 462.76K | 25,144.205 |
Institutional ownership Q4 2020
86.2% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1929 |
Opened positions | 243 |
Closed positions | 120 |
Increased positions | 708 |
Reduced positions | 718 |
13F shares |
Current |
---|---|
Total value | 159.61B |
Total shares | 341.71M |
Total puts | 2.42M |
Total calls | 2M |
Total put/call ratio | 1.2 |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 31M | $14.44B |
BLK Blackrock | 29.5M | $13.74B |
Capital World Investors | 15.98M | $7.44B |
STT State Street | 15.78M | $7.35B |
FMR | 13.02M | $6.07B |
Massachusetts Financial Services | 12.75M | $5.94B |
TROW T. Rowe Price | 12.56M | $5.84B |
Capital Research Global Investors | 9.94M | $4.63B |
MS Morgan Stanley | 7.73M | $3.6B |
Wellington Management | 7.3M | $3.4B |
Financial report summary
?Competition
Bio-Rad Laboratories • Quidel • Mesa Laboratories • Accelerate Diagnostics • Waters • Luminex • Biocept • Reflect Scientific • Illumina • Harvard BioscienceManagement Discussion
- Sales in 2020 were $32.22 billion, an increase of $6.68 billion from 2019. Sales increased $78 million due to acquisitions, net of a divestiture. The favorable effects of currency translation resulted in an increase in revenues of $133 million in 2020. Aside from the effects of acquisitions and currency translation, revenues increased $6.47 billion (25%) primarily due to increased demand. Sales of products that address COVID-19 testing and treatment totaled $6.63 billion in 2020, and were offset in part by lower revenues in the remainder of the business during the first half of 2020. Sales were particularly strong in diagnostic and healthcare markets, due to demand for products supporting customers diagnosing the COVID-19 virus, offset in part by lower sales of other products due to pandemic-related impacts on customer activity. Sales were also strong to customers in pharma and biotech markets where demand was strong for products and services and pandemic-related demand for therapies and vaccines also contributed to growth. Sales to customers in industrial markets decreased primarily due to lower demand from weakened economic conditions related to COVID-19. Sales to these customers returned to positive growth in the fourth quarter of 2020. Sales to academic and government customers decreased due primarily to closure of academic labs during the global pandemic. Sales to these customers returned to positive growth in the third quarter of 2020. Sales growth was particularly strong in North America and Europe and, to a lesser extent, in the Asia-Pacific region.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accident, Africa, Alexandra, announced, attract, attractive, belong, bioscience, breakdown, Brexit, broaden, buy, capability, career, chlorinated, choice, coaching, collaborate, colleague, commuter, companion, consecutive, contemporary, count, crossed, delinquency, dental, disability, disallowed, driven, dye, dynamic, East, Embracing, EMEA, empowered, empowering, ERG, ethnic, ethnicity, excellent, fabric, factory, feedback, feel, gave, gender, Graduate, greatly, hamper, home, Hong, inclusion, inclusive, Influenza, journey, Keith, kind, Kong, launched, leadership, learn, learning, LGBTQ, LIBOR, link, mentoring, Mesa, Middle, mobilized, mortality, motivator, notice, Novasep, onboarding, online, openly, organizational, outflow, outlined, overarching, passionate, perfluorooctanoic, persist, perspective, play, PPE, precautionary, prioritize, prolonged, proven, ramping, recruiting, recruitment, referral, regularly, reinforce, reopen, representation, respiratory, roadmap, role, rotational, SAS, scarce, similarly, situation, size, slowdown, solicit, spectral, spread, stake, Strep, stretch, strive, strongest, successful, successor, sulfonate, summer, syncytial, talent, temporarily, today, true, tuition, Twentieth, unpredictable, unrivaled, vaccine, valuable, vital, voice, worsen, woven
Removed:
accreted, added, Affymetrix, alleged, alleging, allocate, appeal, ascribed, Asia, backlog, biopharmaceutical, bridge, Circuit, combined, community, complaint, consisting, correct, customizable, cytology, Delaware, developer, differential, disposing, District, effected, Elaine, expiring, FEI, filled, financed, forma, fully, histology, injunctive, installed, integration, invalid, investigate, IP, largely, meant, necessarily, noncancelable, operative, partial, percentage, plaintiff, preceding, preliminary, pro, promised, provisionally, qPCR, recording, refinancing, relief, remeasured, remediate, rental, revaluing, Southern, Supreme, title, Ullian, unaudited, unconditionally, unidentified, Unisone, unknown, volatile, waste
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
30 Oct 20
10-Q
2020 Q2
Quarterly report
31 Jul 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
1 Nov 19
10-Q
2019 Q2
Quarterly report
2 Aug 19
10-Q
2019 Q1
Quarterly report
3 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
24 Feb 21
8-K
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results
1 Feb 21
8-K
Results of Operations and Financial Condition
11 Jan 21
8-K
Entry into a Material Definitive Agreement
4 Dec 20
8-K
Regulation FD Disclosure
1 Dec 20
8-K
Departure of Directors or Certain Officers
20 Nov 20
8-K
Thermo Fisher Scientific Reports Third Quarter 2020 Results
21 Oct 20
8-K
Departure of Directors or Certain Officers
14 Sep 20
8-K
Regulation FD Disclosure
10 Sep 20
8-K
Lapse of Offer and Termination of Acquisition Agreement
13 Aug 20
Registration and prospectus
25-NSE
Exchange delisting
15 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
11 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
10 Aug 20
25-NSE
Exchange delisting
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
6 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
5 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
4 Aug 20
SC TO-T/A
Third party tender offer statement (amended)
3 Aug 20
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
9 Apr 19
DEF 14A
Definitive proxy
9 Apr 19
DEF 14A
Definitive proxy
9 Apr 18
DEFA14A
Additional proxy soliciting materials
9 Apr 18
DEFA14A
Additional proxy soliciting materials
15 May 17
DEF 14A
Definitive proxy
3 Apr 17
DEFA14A
Additional proxy soliciting materials
3 Apr 17
DEF 14A
Definitive proxy
4 Apr 16
Other
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
31 May 19
SD
Conflict minerals disclosure
30 May 18
CERTNYS
Certification of approval for NYSE listing
23 Jul 17
SD
Conflict minerals disclosure
30 May 17
CERTNYS
Certification of approval for NYSE listing
15 Mar 17
CERTNYS
Certification of approval for NYSE listing
11 Sep 16
CERTNYS
Certification of approval for NYSE listing
8 Aug 16
SD
Conflict minerals disclosure
30 May 16
UPLOAD
Letter from SEC
9 May 16
Ownership
4
THERMO FISHER SCIENTIFIC / MARC N CASPER ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / Stephen Williamson ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / Mark Stevenson ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / Michel Lagarde ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / Syed A. Jafry ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / PETER E HORNSTRA ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / Michael A Boxer ownership change
1 Mar 21
4
THERMO FISHER SCIENTIFIC / MARC N CASPER ownership change
25 Feb 21
4
THERMO FISHER SCIENTIFIC / Syed A. Jafry ownership change
25 Feb 21
4
THERMO FISHER SCIENTIFIC / Stephen Williamson ownership change
25 Feb 21
Patents
APP
Utility
Systems and Methods for Providing Fluidic Access to a Flow Cell
25 Feb 21
An apparatus includes a fluidic coupler including an opening.
APP
Utility
Ribonucleoprotein Transfection Agents
25 Feb 21
Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells.
APP
Utility
System and Method for Sequencing
25 Feb 21
A sequencing system includes an automated sequencing instrument adapted to determine variant calls for one or more extracted polynucleotide samples with a performance of at least 98.5% raw read accuracy and a run time in a range of 5 hours to 14 hours to determine variant calls for 4 extracted polynucleotide samples using a targeted assay with one DNA pool per sample and an average amplicon size in a range of 100 to 120 bases.
APP
Utility
Method and Apparatus for Quantifying Solutions Comprised of Multiple Analytes
25 Feb 21
Inventors: Mark Selker, Barbara Paldus
APP
Utility
Devices Incorporating Multilane Flow Cell
25 Feb 21
A sensor device includes a substrate having a die attached to the substrate.
Transcripts
2020 Q4
Earnings call transcript
1 Feb 21
2020 Q3
Earnings call transcript
21 Oct 20
2020 Q2
Earnings call transcript
22 Jul 20
2020 Q1
Earnings call transcript
22 Apr 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
23 Oct 19
2019 Q2
Earnings call transcript
24 Jul 19
2019 Q1
Earnings call transcript
24 Apr 19
2018 Q4
Earnings call transcript
30 Jan 19
2018 Q3
Earnings call transcript
24 Oct 18
Reddit threads
What 3 stocks would you pick if you had to pick 3 and throw the password away for 10 years?
1 Mar 21
Rate my pie
1 Mar 21
My biggest take away from every Amazon and Tesla post.
28 Feb 21
Investments you own that you believe have the highest chance of 10X'ing in 5-10 years.
27 Feb 21
Friday 26 February 2021: A discount bot I have created.
26 Feb 21
What additional stock should I pick up?
24 Feb 21
Daily General Discussion and spitballin thread
24 Feb 21
Vlad's testimony in a nutshell
19 Feb 21
stocks I like - for the hedge funds buying tech to track this
19 Feb 21
PLTR 440k YOLO - Holding since November and now loaded up on LEAPS 🚀
19 Feb 21